Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN965924 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-CAMP Responsive Element Binding Protein 1 (CREB1) (pSer129) antibody
- Antibody type
- Polyclonal
- Antigen
- The antiserum was produced against synthesized phosphopeptide derived from human CREB around the phosphorylation site of serine 129 (I-L-SP-R-R).
- Description
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using nonphosphopeptide corresponding to the phosphorylation site.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Epitope
- pSer129
- Vial size
- 100 μg
- Concentration
- 100ug/100ul.
- Storage
- -20°C
Submitted references Platelet-derived growth factor BB induces nuclear export and proteasomal degradation of CREB via phosphatidylinositol 3-kinase/Akt signaling in pulmonary artery smooth muscle cells.
Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene.
PTH induction of transcriptional activity of the cAMP response element-binding protein requires the serine 129 site and glycogen synthase kinase-3 activity, but not casein kinase II sites.
Garat CV, Fankell D, Erickson PF, Reusch JE, Bauer NN, McMurtry IF, Klemm DJ
Molecular and cellular biology 2006 Jul;26(13):4934-48
Molecular and cellular biology 2006 Jul;26(13):4934-48
Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene.
Rothem L, Stark M, Assaraf YG
Molecular pharmacology 2004 Dec;66(6):1536-43
Molecular pharmacology 2004 Dec;66(6):1536-43
PTH induction of transcriptional activity of the cAMP response element-binding protein requires the serine 129 site and glycogen synthase kinase-3 activity, but not casein kinase II sites.
Tyson DR, Swarthout JT, Jefcoat SC, Partridge NC
Endocrinology 2002 Feb;143(2):674-82
Endocrinology 2002 Feb;143(2):674-82
No comments: Submit comment
No validations: Submit validation data